Translational Research Unit, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Dept of Epidemiology and Preclinical Research, Rome, Italy
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology (LJI), La Jolla, CA, USA.
Eur Respir J. 2018 Nov 8;52(5). doi: 10.1183/13993003.01089-2018. Print 2018 Nov.
Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.
抗结核治疗需要≥6 个月,这给世界大部分地区的患者和卫生系统带来了巨大负担。为了清除残留的耐药细菌,预防结核病复发,需要治疗超过 2 个月。然而,大多数仅治疗 2-3 个月的患者将治愈而不复发,不需要延长治疗。能够在治疗早期识别这些患者的检测方法可能会显著有助于减轻治疗负担,而能够识别治疗失败患者的检测方法可能有助于确定针对宿主导向治疗的目标。在这篇综述中,我们总结了预测无复发结核病治愈的生物标志物发现的最新进展。正电子发射断层扫描/计算机断层扫描(PET/CT)扫描测量肺部炎症,增强了我们对“治愈”的理解。一些微生物学和免疫学标志物似乎很有前途,但它们仍需要进行正式验证。同时,还需要新的研究策略来开发可靠的检测方法。